Evaluation of the neutralizing activity of SARS-CoV-2 antibodies, including against variants, and their use in diagnostic and therapeutic products
First written in FY2022-Q1. 2 of 3 entries say "Restated". Latest entry: FY2022-Q3.
No other company in this theme has enough history to compare yet.
- FY2022-Q3RestatedAnnual report
「Beginning with the first-quarter consolidated accounting period, the Company began joint research with Kumamoto University, a national university corporation, to evaluate the performance of antibodies against the SARS-CoV-2 spike protein that it had continuously obtained, including neutralizing activity against viruses including novel coronavirus variants, for potential use in diagnostic and therapeutic products.」
The Company reconfirmed that it had begun joint research with Kumamoto University to evaluate the performance of SARS-CoV-2 antibodies using viruses including variants. - FY2022-Q2RestatedAnnual report
「Beginning with the first-quarter consolidated accounting period, the Company began joint research with Kumamoto University, a national university corporation, to evaluate the performance of antibodies against the SARS-CoV-2 spike protein that it had continuously obtained, including neutralizing activity against viruses including novel coronavirus variants, for potential use in diagnostic and therapeutic products.」
The Company reconfirmed that it had begun joint research with Kumamoto University to evaluate the performance of SARS-CoV-2 antibodies using viruses including variants. - FY2022-Q1First statedAnnual report
「The Company began joint research with Kumamoto University, a national university corporation, to evaluate the performance of antibodies against the SARS-CoV-2 spike protein that it had continuously obtained, including neutralizing activity against viruses including novel coronavirus variants, for potential use in diagnostic and therapeutic products.」
The Company began joint research with Kumamoto University on antibodies against the SARS-CoV-2 spike protein that it had continuously obtained, newly describing efforts to link performance evaluations, including neutralizing activity using viruses including variants, to their use in diagnostic and therapeutic products.